LB0005 12-week results of a phase 2B dose-ranging study of...

LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis

Keystone, E., Taylor, P., Genovese, M., Schlichting, D., Beattie, S., Gaich, C., Fidelus Gort, R., Luchi, M., Macias, W. L.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
71
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2012-eular.1965
Date:
June, 2012
File:
PDF, 74 KB
english, 2012
Conversion to is in progress
Conversion to is failed